Transaction DateRecipientSharesTypePriceValue
18th August 2020John T. Maxwell3,000Open or private sale$8.00$24,000.00
30th June 2020Keith J Kendall148Payment by withholding$4.86$719.28
30th June 2020Keith J Kendall333Exercise of derivative$0.00
30th June 2020Alexander Mark Schobel333Exercise of derivative$0.00
30th June 2020Alexander Mark Schobel94Payment by withholding$4.86$456.84
23rd June 2020James S Scibetta3,600Other acquisition or disposition$0.00
4th June 2020Keith J Kendall50,000Open or private sale$5.11$255,310.00
31st May 2020Alexander Mark Schobel14,572Exercise of derivative$0.00
31st May 2020Keith J Kendall6,492Payment by withholding$4.87$31,616.04
31st May 2020Keith J Kendall14,572Exercise of derivative$0.00
Aquestive Therapeutics
Aquestive Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Aquestive Therapeutics, Inc. has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole)

Ticker: AQST
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1398733
Employees: 232
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags